BriaCell Therapeutics

Yahoo Finance • last month

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Therapeutics Corp. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology... Full story

Yahoo Finance • 2 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story

Yahoo Finance • 2 months ago

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets... Full story

Yahoo Finance • 2 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story

Yahoo Finance • 2 years ago

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

After only 3 cycles, patient experienced a remarkable improvement of eye-bulging “proptosis” caused by orbital metastatic breast cancer tumor behind the eye. Significant ocular pain reduction recorded.Heavily treated patient had 7 prior fa... Full story

Yahoo Finance • 2 years ago

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, June 27, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage immunotherapy company driven to fight cancer and... Full story

Yahoo Finance • 2 years ago

BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.

Prevail Partners, LLC to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing thirty (30) trading day VWAP. Prevail InfoWorks, Inc. to act as Contract Rese... Full story

Yahoo Finance • 2 years ago

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR

15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment.The Bria-IMT™ combination... Full story